Literature DB >> 33588853

Implications of the ACC/AHA risk score for prediction of heart failure: the Rotterdam Study.

Banafsheh Arshi1, Jan C van den Berge2, Bart van Dijk1, Jaap W Deckers1, M Arfan Ikram1, Maryam Kavousi3.   

Abstract

BACKGROUND: Despite the growing burden of heart failure (HF), there have been no recommendations for use of any of the primary prevention models in the existing guidelines. HF was also not included as an outcome in the American College of Cardiology/American Heart Association (ACC/AHA) risk score.
METHODS: Among 2743 men and 3646 women aged ≥ 55 years, free of HF, from the population-based Rotterdam Study cohort, 4 Cox models were fitted using the predictors of the ACC/AHA, ARIC and Health-ABC risk scores. Performance of the models for 10-year HF prediction was evaluated. Afterwards, performance and net reclassification improvement (NRI) for adding NT-proBNP to the ACC/AHA model were assessed.
RESULTS: During a median follow-up of 13 years, 429 men and 489 women developed HF. The ARIC model had the highest performance [c-statistic (95% confidence interval [CI]): 0.80 (0.78; 0.83) and 0.80 (0.78; 0.83) in men and women, respectively]. The c-statistic for the ACC/AHA model was 0.76 (0.74; 0.78) in men and 0.77 (0.75; 0.80) in women. Adding NT-proBNP to the ACC/AHA model increased the c-statistic to 0.80 (0.78 to 0.83) in men and 0.81 (0.79 to 0.84) in women. Sensitivity and specificity of the ACC/AHA model did not drastically change after addition of NT-proBNP. NRI(95%CI) was - 23.8% (- 19.2%; - 28.4%) in men and - 27.6% (- 30.7%; - 24.5%) in women for events and 57.9% (54.8%; 61.0%) in men and 52.8% (50.3%; 55.5%) in women for non-events.
CONCLUSIONS: Acceptable performance of the model based on risk factors included in the ACC/AHA model advocates use of this model for prediction of HF risk in primary prevention setting. Addition of NT-proBNP modestly improved the model performance but did not lead to relevant discrimination improvement in clinical risk reclassification.

Entities:  

Keywords:  Heart failure; NT-proBNP; Prediction; Primary prevention

Mesh:

Substances:

Year:  2021        PMID: 33588853      PMCID: PMC7885616          DOI: 10.1186/s12916-021-01916-7

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   8.775


  35 in total

Review 1.  Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review.

Authors:  Jaime Latour-Pérez; Francisco Javier Coves-Orts; Carmen Abad-Terrado; Víctor Abraira; Javier Zamora
Journal:  Eur J Heart Fail       Date:  2005-11-21       Impact factor: 15.534

2.  Diagnostic interpretation of electrocardiograms in population-based research: computer program research physicians, or cardiologists?

Authors:  M C de Bruyne; J A Kors; A W Hoes; D A Kruijssen; J W Deckers; M Grosfeld; G van Herpen; D E Grobbee; J H van Bemmel
Journal:  J Clin Epidemiol       Date:  1997-08       Impact factor: 6.437

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

4.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

Authors:  Karl Swedberg; John Cleland; Henry Dargie; Helmut Drexler; Ferenc Follath; Michel Komajda; Luigi Tavazzi; Otto A Smiseth; Antonello Gavazzi; Axel Haverich; Arno Hoes; Tiny Jaarsma; Jerzy Korewicki; Samuel Lévy; Cecilia Linde; José-Luis Lopez-Sendon; Markku S Nieminen; Luc Piérard; Willem J Remme
Journal:  Eur Heart J       Date:  2005-05-18       Impact factor: 29.983

5.  Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension.

Authors:  David Conen; Andreas Zeller; Matthias Pfisterer; Benedict Martina
Journal:  Am J Cardiol       Date:  2005-11-21       Impact factor: 2.778

6.  Incident heart failure prediction in the elderly: the health ABC heart failure score.

Authors:  Javed Butler; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Rhonda Belue; Nicolas Rodondi; Melissa Garcia; Douglas C Bauer; Suzanne Satterfield; Andrew L Smith; Viola Vaccarino; Anne B Newman; Tamara B Harris; Peter W F Wilson; Stephen B Kritchevsky
Journal:  Circ Heart Fail       Date:  2008-07       Impact factor: 8.790

7.  Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study.

Authors:  Joost H W Rutten; Francesco U S Mattace-Raso; Ewout W Steyerberg; Jan Lindemans; Albert Hofman; Renske G Wieberdink; Monique M B Breteler; Jacqueline C M Witteman; Anton H van den Meiracker
Journal:  Hypertension       Date:  2010-01-18       Impact factor: 10.190

8.  Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova; John Robson; Margaret May; Peter Brindle
Journal:  BMJ       Date:  2007-07-05

9.  Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Sunil K Agarwal; Lloyd E Chambless; Christie M Ballantyne; Brad Astor; Alain G Bertoni; Patricia P Chang; Aaron R Folsom; Max He; Ron C Hoogeveen; Hanyu Ni; Pedro M Quibrera; Wayne D Rosamond; Stuart D Russell; Eyal Shahar; Gerardo Heiss
Journal:  Circ Heart Fail       Date:  2012-05-15       Impact factor: 8.790

10.  Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study.

Authors:  Maarten J G Leening; Maryam Kavousi; Jan Heeringa; Frank J A van Rooij; Jolande Verkroost-van Heemst; Jaap W Deckers; Francesco U S Mattace-Raso; Gijsbertus Ziere; Albert Hofman; Bruno H Ch Stricker; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2012-03-03       Impact factor: 8.082

View more
  1 in total

1.  Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus.

Authors:  Alexander A Berezin; Michael Lichtenauer; Elke Boxhammer; Ivan M Fushtey; Alexander E Berezin
Journal:  Front Physiol       Date:  2022-05-16       Impact factor: 4.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.